

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUTCHMED (China) Limited**

**和黃醫藥（中國）有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 13)**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is issued pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Please refer to the attached announcement which has been published by HUTCHMED (China) Limited on the website of the U.K. Regulatory Information Service on December 30, 2024.

By Order of the Board

**Edith Shih**

*Non-executive Director and Company Secretary*

Hong Kong, December 30, 2024

As at the date of this announcement, the Directors of the Company are:

**Chairman and Non-executive Director:**

Dr Dan ELDAR

**Executive Directors:**

Dr Weiguo SU

*(Chief Executive Officer and  
Chief Scientific Officer)*

Mr CHENG Chig Fung, Johnny

*(Chief Financial Officer)*

**Non-executive Directors:**

Ms Edith SHIH

Ms Ling YANG

**Independent Non-executive Directors:**

Mr Paul Rutherford CARTER

*(Senior Independent Director)*

Dr Renu BHATIA

Dr Chaohong HU

Mr Graeme Allan JACK

Professor MOK Shu Kam, Tony

## Blocklisting Six Monthly Return

**Hong Kong, Shanghai & Florham Park, NJ — Monday, December 30, 2024:** HUTCHMED (China) Limited (“[HUTCHMED](#)” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) announces the following blocklisting six monthly return:

|   |  |
|---|--|
| 1. Name of applicant:   | HUTCHMED (China) Limited   |
| 2. Name of scheme:  | Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 HUTCHMED Share Option Scheme”)  |
| 3. Period of return:  | From June 29, 2024 to December 28, 2024  |
| 4. Balance under scheme from previous return:   | 2015 HUTCHMED Share Option Scheme: 46,743,768 ordinary shares of US\$0.1 each  |
| 5. The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: | 2015 HUTCHMED Share Option Scheme: Nil   |
| 6. Number of securities issued/allotted under scheme during period:   | 2015 HUTCHMED Share Option Scheme: 241,375   |
| 7. Balance under scheme not yet issued/allotted at end of the period:   | 2015 HUTCHMED Share Option Scheme: 46,502,393 ordinary shares of US\$0.1 each  |
| 8. Number and class of securities originally listed and the date of admission:  | 25,198,880 ordinary shares of US\$0.1 each admitted on June 17, 2019 (to replace the Company’s previous block admission schemes following the Company’s share subdivision which took effect on May 30, 2019) |
| 9. Total number of securities in issue at the end of the period:  | 871,601,095 ordinary shares of US\$0.1 each  |
| Name of contact:  | Weiguo Su  |
| Address of contact:   | Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong  |
| Telephone number of contact:  | +852 2121 8200   |

### About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit [www.hutch-med.com](http://www.hutch-med.com) or follow us on [LinkedIn](#).

## CONTACTS

### Investor Enquiries

+852 2121 8200 / [ir@hutch-med.com](mailto:ir@hutch-med.com)

### Media Enquiries

Ben Atwell / Alex Shaw, FTI Consulting +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) / [HUTCHMED@fticonsulting.com](mailto:HUTCHMED@fticonsulting.com)

Zhou Yi, Brunswick +852 9783 6894 (Mobile) / [HUTCHMED@brunswickgroup.com](mailto:HUTCHMED@brunswickgroup.com)

### Nominated Advisor

Atholl Tweedie / Freddy Crossley /  
Rupert Dearden, Panmure Liberum +44 (20) 7886 2500